Sunovion Pharmaceuticals Inc.

Apsinterm LLC

Sepracor, Inc.

Harold Scott Wilkinson

John R Snoonian

Seth C Hopkins

Kenneth S Koblan

Haitao Zhang

Roger P Bakale

Surendra Singh

Chris Hugh Senanayake

Charles P Vandenbossche

Stefan G Koenig

Hang Zhao

Dhileepkumar Krishnamurthy

Zhengxu Han

Derek Pflum

Robert Joseph Prytko

Michael Joseph Sizensky

Nandkumar Nivritti Bhogle

Gerald J Tanoury

Kostas Saranteas

Shahla Jamzad

Patrick Mousaw

Andrea Bauer

Takahiko Hashizuka

Xiaoxia Chen

Cai Gu Huang

Philip James Bonasia

Sharon M Laughlin

Susan S D'Souza

Andrei A Zlota

Kevin Plunkett

Norman Kim

John Snoonian

Michael Sizensky

Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.

Nonracemic mixtures and uses thereof

The various aspects present inventions provide various crystalline forms of (S)-(&#x2212;)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.

Crystal forms and production methods thereof

Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.

Salts, crystal forms, and production methods thereof

The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.

Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure.

Preparation of chiral amides and amines

Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms of transnorsertraline, methods of making the compositions, and methods for their use for the treatment of CNS diseases, including depression.

Formulations, salts and polymorphs of transnorsertraline and uses thereof

Growing community of inventors

Westborough, MA, United States of America

Harold Scott Wilkinson